Generic formulation lowers IOP effectively

Branded drug with lower concentration does offer a better side effect profile than generics

Related Videos
Related Content

Making the grade: FDA approves first biosimilar product for retinal diseases

November 1st 2021

Advancement in TED treatment is a bright spot

June 30th 2021

Comparable conscious sedation methods address individual patient needs

April 14th 2021

Investigators uncover health care disparities among US patients

April 2nd 2021

Investigators zoom in on future of dry eye treatment

March 2nd 2021

Analyzing opioid prescription patterns of US retina specialists

November 16th 2020

Making the grade: FDA approves first biosimilar product for retinal diseases

November 1st 2021

Advancement in TED treatment is a bright spot

June 30th 2021

Comparable conscious sedation methods address individual patient needs

April 14th 2021

Investigators uncover health care disparities among US patients

April 2nd 2021

Investigators zoom in on future of dry eye treatment

March 2nd 2021

Analyzing opioid prescription patterns of US retina specialists

November 16th 2020

Making the grade: FDA approves first biosimilar product for retinal diseases

November 1st 2021

Advancement in TED treatment is a bright spot

June 30th 2021

Comparable conscious sedation methods address individual patient needs

April 14th 2021

Investigators uncover health care disparities among US patients

April 2nd 2021

Investigators zoom in on future of dry eye treatment

March 2nd 2021

Analyzing opioid prescription patterns of US retina specialists

November 16th 2020
Advertise
Privacy
Editorial
Terms and Conditions
Contact Us
Do Not Sell My Personal Information
Job Board
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.